@article{d8e0becac97a4f97bf76725559ecf7ab,
title = "Understanding Patterns of Missingness in Acute Ischemic Stroke Trials: A Secondary Analysis of Pooled Participant-Level Follow-Up Data",
keywords = "albumin, ethnicity, hyperglycemia, ischemic stroke, odds ratio",
author = "{De Havenon}, Adam and Aaron Bangad and Skolarus, {Lesli E.} and Aldridge, {Chad M.} and Braun, {Robynne G.} and Cole, {John W.} and Cramer, {Steven C.} and Lindgren, {Arne G.} and Sunmonu, {N. Abimbola} and Worrall, {Bradford B.} and Lohse, {Keith R.}",
note = "Funding Information: Dr de Havenon receives research funding from the National Institutes of Health (NIH), consultant fees from Integra and Novo Nordisk, royalty fees from UpToDate, and equity in TitinKM and Certus. Dr Cramer serves as a consultant for Abbvie, Constant Therapeutics, MicroTransponder, Neurolutions, SanBio, Panaxium, NeuExcell, Elevian, Medtronic, Helius, Omniscient, and TRCare. Dr Lindgren reports personal fees from Bayer, NovoNordisk, Astra Zeneca, and BMS Pfizer. Dr Skolarus reports research funding from NIH and American Heart Association, and employment by University of Michigan and Northwestern. The other authors report no conflicts. ",
year = "2023",
month = may,
day = "1",
doi = "10.1161/STROKEAHA.122.042168",
language = "English (US)",
volume = "54",
pages = "E201--E202",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "5",
}